The White House Former COVID Czar Spreads Misinformation to Sell Fall Booster
What this video covers
Dr. Vinay Prasad accuses Dr. Ashish Jha — the former White House COVID-19 response coordinator — of spreading misinformation to promote the fall 2023 COVID booster, particularly around children. The video parallels a Substack essay in which Prasad itemizes what he considers Jha’s misleading claims and rebuts them one by one.
Prasad’s central arguments: the risk of severe COVID to healthy children was already very low and had fallen further with widespread natural immunity; the FDA authorized pediatric COVID vaccines on the basis of non-inferior antibody levels rather than randomized trials powered to show reductions in severe disease; and the observational studies used to justify vaccinating young children were hopelessly confounded because the families who rushed to vaccinate differed fundamentally from those who didn’t. He argues Jha’s public statements implied a certainty about pediatric benefit that the evidence could not support.
The video exemplifies Prasad’s combative style toward public health officials he views as having oversold interventions. Jha, for his part, was a prominent advocate of the updated boosters, arguing they remained important protection, especially for higher-risk groups — a position Prasad treats as marketing rather than science.
Key points
- Prasad accuses former White House COVID coordinator Ashish Jha of making misleading public claims about COVID risk and booster benefit, particularly regarding children, to sell the fall 2023 booster.
- He argues the risk of severe disease to healthy children was already very low and only lower with widespread natural immunity, so the absolute benefit of boosting kids was tiny.
- According to Prasad, the FDA authorized pediatric vaccines on non-inferior antibody data — not on randomized trials demonstrating fewer hospitalizations or deaths in children — which he calls an evidentiary failure.
- He contends observational studies of pediatric vaccination are hopelessly confounded: families who vaccinated early differed systematically from those who didn’t, making comparisons unreliable.
- Prasad argues the updated booster targeted an old strain while most children had already been infected, and says there was no evidence it would further reduce severe disease or death in kids.
- He frames Jha’s advocacy as misinformation in service of a pharmaceutical product — reversing the usual direction of the term.
- Context: Jha and other officials argued boosters remained a sensible precaution and that population-level benefits justified broad recommendation; they disputed that their statements were misleading.